References
- Ahmed N. K., Felsted R. L., Bachur N. R. Heterogeneity of anthracycline antibiotic carbonyl reductases in mammalian livers. Biochem. Pharmacol. 1978; 27(23)2713–2719, [PUBMED], [INFOTRIEVE]
- Ahmed N. K., Felsted R. L., Bachur N. R. Comparison and characterization of mammalian xenobiotic ketone reductases. J. Pharmacol. Exp. Ther. 1979; 209: 12–19, [PUBMED], [INFOTRIEVE]
- Asami M., Shigeta A., Tanaka Y. Disposition of CS‐670, a novel nonsteroidal anti‐inflammatory drug, and its metabolites in healthy human volunteers. Chirality 1996; 8(2)207–213, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Atalla A., Breyer‐Pfaff U., Maser E. Purification and characterization of oxidoreductases catalyzing carbonyl reduction of the tobacco‐specific nitrosamine 4‐methylnitrosamino‐1‐(3‐pyridyl)‐1‐butanone (NNK) in human liver cytosol. Xenobiotica 2000; 30(8)755–769, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Avramopoulos D., Cox T., Forrest G. L., Chakravarti A., Antonarakis S. Linkage mapping of the carbonyl reductase (CBR) gene on human chromosome 21 using a DNA polymorphism in the 3′ untranslated region. Genomics 1992; 13(2)447–448, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Barski O. A., Gabbay K. H., Grimshaw C. E., Bohren K. M. Mechanism of human aldehyde reductase: characterization of the active site pocket. Biochemistry 1995; 34(35)11264–11275, [PUBMED], [INFOTRIEVE]
- Benedetti S. M., Pianezzola E., Fraier D., Castelli M. G., Dostert P. Stereoselectivity of idarubicin reduction in various animal species and humans. Xenobiotica 1991; 21(4)473–480
- Benedetti S. M., Fraier D., Pianezzola E., Castelli M. G., Dostert P., Gianni L. Stereoselectivity of iododoxorubicin reduction in various animal species and humans. Xenobiotica 1993; 23(2)115–121, [CSA]
- Bennett M. J., Schlegel B. P., Jez J. M., Penning T. M., Lewis M. Structure of 3 alpha‐Hydroxysteroid/Dihydrodiol Dehydrogenase Complexed with NADP +. Biochemistry 1996; 35(33)10702–10711, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Bianchet M. A., Foster C., Faig M., Talalay P., Amzel L. M. Structure and mechanism of cytosolic quinone reductases. Biochem. Soc. Trans. 1999; 27(4)610–615, [PUBMED], [INFOTRIEVE], [CSA]
- Bjornsson T. D., Callaghan J. T., Einolf H. J., Fischer V., Gan L., Grimm S., Kao J., King S. P., Miwa G., Ni L., Kumar G., McLeod J., Obach R. S., Roberts S., Roe A., Shah A., Snikeris F., Sullivan J. T., Tweedie D., Vega J. M., Walsh J., Wrighton S. A. The conduct of in vitro and in vivo drug–drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. 2003; 31(7)815–832, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Blum A., Raum A., Martin H. J., Maser E. Human 11β‐hydroxysteroid dehydrogenase 1/carbonyl reductase: additional domains for membrane attachment?. Chem. Biol. Interact. 2001; 130–132: 749–759, [CROSSREF]
- Boxenbaum H., Gillespie T., Heck K., Hahne W. Human dolasetron pharmacokinetics: I. Disposition following single‐dose intravenous administration to normal male subjects. Biopharm. Drug Dispos. 1992; 13: 693–701, [PUBMED], [INFOTRIEVE]
- Boxenbaum H., Gillespie T., Heck K., Hahne W. Human dolasetron pharmacokinetics: II. Absorption and disposition following single‐dose oral administration to normal male subjects. Biopharm. Drug Dispos. 1993; 14(2)131–141, [PUBMED], [INFOTRIEVE]
- Breyer‐Pfaff U., Nill K. Stereoselective reversible ketone formation from 10‐hydroxylated nortriptyline metabolites in human liver. Xenobiotica 1995; 25(12)1311–1325, [CSA]
- Breyer‐Pfaff U., Nill K. High‐affinity stereoselective reduction of the enantiomers of ketotifen and of ketonic nortriptyline metabolites by aldo‐keto reductases from human liver. Biochem. Pharmacol. 2000; 59: 249–260, [CROSSREF], [CSA]
- Brooks D. W., Mazdiyasni H., Grothaus P. G. Asymmetric microbial reduction of prochiral 2,2—disubstituted cycloalkanediones. J. Org. Chem. 1987; 52: 3223–3232
- Bühler H., Perschel F. H., Fitzner R., Hierholzer K., Lichtenstein I., Siebe H. Endogenous inhibitors of 11β‐OHSD: existence and possible significance. Steroids 1994; 59: 131–135, [CROSSREF], [CSA]
- Caldwell J. The biochemical pharmacology of fenofibrate. Cardiology 1989; 76(suppl. 1)33–44, [PUBMED], [INFOTRIEVE]
- Chang Q., Harter T. M., Rikimaru L. T., Petrash J. M. Aldo‐keto reductases as modulators of stress response. Chem. Biol. Interact. 2003; 143–144: 325–332, [CROSSREF]
- Chem. Biol. Interact. 2003; 143–144: 1–631
- Crespi C. E., Miller V. P. The use of heterologously expressed drug metabolizing enzymes—state of the art and prospects for the future. Pharmacol. Ther. 1999; 84: 121–131, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Cullen J. J., Hinkhouse M. M., Grady M., Gaut A. W., Liu J., Zhang Y. P., Darby Weydart C. J., Domann F. E., Oberley L. W. Dicumerol inhibition of NADPH: quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide‐mediated mechanism. Cancer Res. 2003; 63(17)5513–5520, [PUBMED], [INFOTRIEVE]
- Dalmadi B., Leibinger J., Szeberényi S., Borbás T., Farkas S., Szombathelyi Z., Tihanyi K. Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metab. Dispos. 2003; 31(5)631–636, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Danielson P. B. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr. Drug Metab. 2002; 3(6)561–597, [PUBMED], [INFOTRIEVE]
- Deyashiki Y., Taniguchi H., Amano T., Nakayama T., Hara A., Sawada H. Structural and functional comparison of two human liver dihydrodiol dehydrogenases associated with 3α‐hydroxysteroid dehydrogenase activity. Biochem. J. 1992; 282: 741–746, [PUBMED], [INFOTRIEVE]
- Diederich S., Grossman C., Hanke B., Quinkler M., Herrmann M., Bahr V., Oelkers W. In the search for specific inhibitors of human 11β‐hydroxysteroid dehydrogenase (11β‐HSDs): chenodeoxycholic acid selectively inhibits 11β‐HSD‐1. Eur. J. Endocrinol. 2000; 142(2)200–207, [PUBMED], [INFOTRIEVE], [CSA]
- Donato M. T., Castell J. V. Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies. Clin. Pharmacokinet. 2003; 42(2)153–178, [PUBMED], [INFOTRIEVE], [CSA]
- Dow J., Berg C. Stereoselectivity of the carbonyl reduction of dolasetron in rats, dogs, and humans. Chirality 1995; 7: 342–348, [PUBMED], [INFOTRIEVE], [CSA]
- Draper N., Echwald S. M., Lavery G. G., Walker E. A., Fraser R., Davies E., Sørensen T. I.A., Astrup A., Adamski J., Hewison M., Connell J. M., Pedersen O., Stewart P. M. Association studies between microsatellite markers with the gene encoding human 11β‐hydroxysteroid dehydrogenase type 1 and body mass index, waist to hip ratio, and glucocorticoid metabolism. J. Clin. Endocrinol. Metab. 2002; 87(11)4984–4990, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ehrig T., Bohren K. M., Prendergast F. G., Gabbay K. H. Mechanism of aldose reductase inhibition: binding of NADP + /NADPH and alrestatin‐like inhibitors. Biochemistry 1994; 33(23)7157–7165, [PUBMED], [INFOTRIEVE]
- Eyles D. W., Pond S. M. Stereospecific reduction of haloperidol in human tissues. Biochem. Pharmacol. 1992; 44(5)867–871, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Felsted R. L., Bachur N. R. Mammalian carbonyl reductases. Drug Metab. Rev. 1980; 11(1)1–60, [PUBMED], [INFOTRIEVE]
- Forrest G. L., Gonzales B. Carbonyl reductase. Chem. Biol. Interact. 2000; 129: 21–40, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Foster C. E., Bianchet M. A., Talalay P., Faig M., Amzel M. Structures of mammalian cytosolic quinone reductases. Free Radic. Biol. Med. 2000; 29(3/4)241–245, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gelernter‐Yaniv L., Feng N., Sebring N. G., Hichberg Z., Yanovski J. A. Associations between a polymorphism in the 11β‐hydroxysteroid dehydrogenase type 1 gene and body composition. Int. J. Obes. 2003; 27: 983–986, [CROSSREF], [CSA]
- Glue P., Clement R. P. Cytochrome P450 enzymes and drug metabolism—basic concepts and methods of assessment. Cell. Mol. Neurobiol. 1999; 19(3)309–323, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Greber T. F., Olah T. V., Gilbert J. D., Porras A. G., Hichens M. Determination of L‐691,121, a new class III antiarrhythmic, and its principal metabolite in plasma by differential radioimmunoassy. J. Pharm. Biomed. Anal. 1994; 12(4)483–492, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gross A. S., Somogyi A., Eichelbaum M. Stereoselective drug metabolism and drug interactions. Handb. Exp. Pharmacol. 2003; 153: 313–339, (Stereochemical Aspects of Drug Action and Disposition)
- Guarna A., Occhiato E. G., Spinetti L. M., Vallecchi M. E., Scarpi D. Baker's yeast reduction of prochiral γ‐nitroketones: enantioselective synthesis of (S)‐4‐nitroalcohols. Tetrahedron 1995; 51(6)1775–1788, [CROSSREF]
- Guengerich F. P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol. 2001; 14(6)611–650, [PUBMED], [INFOTRIEVE], [CSA]
- Herber R., Hercelin B., Van Cantfort J., de Graeve J., Fournel‐Gigleux S., Taguchi T., Magdalou J. Reduction and glucuonidation of naftazone by human and rat liver microsomes. Drug Metab. Dispos. 1995; 23(12)1305–1314, [PUBMED], [INFOTRIEVE], [CSA]
- Hermans J. J.R., Thijssen H. H.W. The in vitro ketone reduction of warfarin and analogs. Substrate stereoselectivity, product stereoselectivity and species differences. Biochem. Pharmacol. 1989; 38(19)3365–3370, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hult M., Jörnvall H., Oppermann U. C.T. Selective inhibition of human type 1 11β‐hydroxysteroid dehydrogenase by synthetic steroids and xenobiotics. FEBS Lett. 1998; 441(1)25–28, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hult M., Nobel C. S.I., Abrahmsen L., Nicoll‐Griffith D. A., Jörnvall H., Oppermann U. C.T. Novel enzymological properties of human 11β‐hydroxysteroid dehydrogenase type 1. Chem. Biol. Interact. 2001; 130–132: 805–814, [CROSSREF]
- Hyndman D., Bauman D. R., Heredia V. V., Penning T. M. The aldo‐keto reductase superfamily homepage. Chem. Biol. Interact. 2003; 143–144: 621–631, [CROSSREF]
- Inaba T., Kovacs J. Haloperidol reductase in human and guinea pig livers. Drug Metab. Dispos. 1989; 17(3)330–333, [PUBMED], [INFOTRIEVE]
- Iwata N., Inazu N., Hara S., Yanase T., Kano S., Endo T., Kruiiwa F., Sato Y., Satoh T. Interindividual variability of carbonyl reductase levels in human livers. Biochem. Pharmacol. 1993; 45(8)1711–1714, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Jacobs J. W., McFarland J. T., Wainer I., Jeanmaier D., Ham C., Hamm K., Wnuk M., Lam M. Electronic substituent effects during the liver alcohol dehydrogenase catalyzed reduction of aromatic aldehydes. Biochemistry 1974; 13(1)60–64, [PUBMED], [INFOTRIEVE]
- Jamieson P. M., Chapman K. E., Edwards C. R., Seckl J. R. 11β‐Hydroxysteroid dehydrogenase is an exclusive 11β‐reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology 1995; 136(11)4754–4761, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jamieson P. M., Walker B. R., Chapman K. E., Andrew R., Rossiter S., Seckl J. R. 11β‐Hydroxysteroid dehydrogenase type 1 is a predominant 11β‐reductase in the intact perfused rat liver. J. Endocrinology 2000; 165(3)685–692
- Jez J. M., Penning T. M. The aldo‐keto reductase (AKR) superfamily: an update. Chem. Biol. Interact. 2001; 130–132: 499–525
- Jörnvall H., Nordling E., Persson B. Multiplicity of eukaryotic ADH and other MDR forms. Chem. Biol. Interact. 2003; 143–144: 255–261
- Kishimoto M., Kawamori R., Kamada T., Inaba T. Carbonyl reductase activity for acetohexamide in human erythrocytes. Drug Metab. Dispos. 1994; 22(3)367–370, [PUBMED], [INFOTRIEVE], [CSA]
- Kudo S., Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin. Pharmacokinet. 1999; 37(6)435–456, [PUBMED], [INFOTRIEVE], [CSA]
- Kume T., Iwasa H., Shiraishi H., Yokoi T., Nagashima K., Otsuka M., Terada T., Takagi T., Hara A., Kamataki T. Characterization of a novel variant (S145C/L311V) of 3α‐hydroxysteroid/dihydrodiol dehydrogenase in human liver. Pharmacogenetics 1999; 9(6)763–771, [PUBMED], [INFOTRIEVE], [CSA]
- Kume T., Ohashi N., Sugihara J., Yoshikawa M. Studies on the metabolic fate of TA‐510, a hepatic anti‐inflammatory agent (II): metabolism after oral administration to rats, dogs and human. Yakubutsu Dotai 2000; 15(4)327–337, [CSA]
- Lakshmi V., Nath N., Muneyyirci‐Delale O. Characterization of 11β‐hydroxysteroid dehydrogenase of human placenta: evidence for the existence of two species of 11β‐hydroxysteroid dehydrogenase. J. Steroid Biochem. Mol. Biol. 1993; 45(5)391–397, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Lawrence R. F., Rettie A. E., Eddy A. C., Trager W. F. Chemical synthesis, absolute configuration, and stereochemistry of formation of 10‐hydroxywarfarin: a major oxidative metabolite of (+)‐(R)‐warfarin from hepatic microsomal preparations. Chirality 1990; 2(2)96–105, [PUBMED], [INFOTRIEVE], [CSA]
- Le Bot M. A., Bégué J. M., Kernaleguen D., Robert J., Ratanasavanh D., Guédes Y., Riché C., Guillouzo A. Metabolism of doxorubicin, epirubicin and daunorubicin by human and rat hepatocytes in primary culture. Colloque INSERM 1988; 164: 365–370, (Liver Cells Drugs)[CSA]
- Long D. J., II, Jaiswal A. K. NRH: quinone oxidoreductase2 (NQO2). Chem. Biol. Interact. 2000; 129: 99–112, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Loveless H., Arena E., Felsted R. L., Bachur N. R. Comparative mammalian metabolism of adriamycin and daunorubicin. Cancer Res. 1978; 38: 593–598
- Low S. C., Chapman K. E., Edwards C. R.W., Seckl J. R. ‘Liver‐type’ 11β‐hydroxysteroid dehydrogenase cDNA encodes reductase but not dehydrogenase activity in intact mammalian COS‐7 cells. J. Mol. Endocrinol. 1994; 13(2)167–174, [PUBMED], [INFOTRIEVE], [CSA]
- Maser E. Xenobiotic carbonyl reduction and physiological steroid oxidoreduction. The pluripotency of several hydroxysteroid dehydrogenases. Biochem. Pharmacol. 1995; 49(4)421–440, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Maser E. Stress, hormonal changes, alcohol, food constituents and drugs: factors that advance the incidence of tobacco smoke‐related cancer?. Trends Pharmacol. Sci. 1997; 18(8)270–275, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Maser E., Gebel T., Netter K. J. Carbonyl reduction of metyrapone in human liver. Biochem. Pharmacol. 1991; 42: S93–S98, (Suppl.)[PUBMED], [INFOTRIEVE], [CROSSREF]
- Maser E., Stinner B., Atalla A. Carbonyl reduction of 4‐(methylnitrosamino)‐1‐(3‐pyridyl)‐1‐butanone (NNK) by cytosolic enzymes in human liver and lung. Cancer Lett. 2000; 148: 135–144, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Maser E., Völker B., Friebertshäuser J. 11β‐Hydroxysteroid dehydrogenase type I from human liver: dimerization and enzyme cooperativity support its postulated role as a glucocorticoid reductase. Biochemistry 2002; 41(7)2459–2465, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Maser E., Friebertshäuser J., Völker B. Purification, characterization and NNK carbonyl reductase activities of 11β‐hydroxysteroid dehydrogenase type I from human liver: enzyme cooperativity and significance in the detoxification of a tobacco‐derived carcinogen. Chem. Biol. Interact. 2003; 143–144: 435–448, [CROSSREF]
- Matsuura K., Bunai Y., Ohya I., Hara A., Nakanishi M., Sawada H. Ultrastructural localization of carbonyl reductase in mouse lung. Histochem. J. 1994; 26(4)311–316, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- McMahon R. E., Marshall F. J., Culp H. W. The nature of the metabolites of acetohexamide in the rat and in the human. J. Pharmacol. Exp. Therap. 1965; 149(2)272–279
- Midha K. K., Hawes E. M., Hubbard J. W. Interconversion between haloperidol and reduced haloperidol in humans. J. Clin. Psychopharm. 1987; 7(5)362–364
- Miyabe Y., Amano T., Deyashiki Y., Hara A., Tsukada F. Kinetic studies of the inhibition of a human liver 3α‐hydroxysteroid/dihydrodiol dehydrogenase isozyme by bile acids and anti‐inflammatory drugs. Biol. Pharm. Bull. 1995; 18: 9–12, [PUBMED], [INFOTRIEVE], [CSA]
- Monder C., Shackleton C. H. 11 Beta‐hydroxysteroid dehydrogenase: fact or fancy?. Steroids 1984; 44(5)383–417, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Moody G. C., Griffin S. J., Mather A. N., McGinnity D. F., Riley R. J. Fully automated analysis of activities catalyzed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica 1999; 29(1)53–75, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Moreland T. A., Hewick D. S. Studies on a ketone reductase in human and rat liver and kidney soluble fraction using warfarin as a substrate. Biochem. Pharmacol. 1975; 24(21)1953–1957, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Nagata O., Takahara E., Inomata N., Kato H. Metabolic fate of HY‐770. (IV). Disposition of the metabolites and species differences and mechanism of metabolism in rats, dogs, rabbits and human. Yakubutsu Dotai 1992; 7(3)299–313
- Nakanishi M., Deyashiki Y., Ohshima K., Hara A. Cloning, expression, and tissue distribution of mouse tetrameric carbonyl reductase. identity with an adipocyte 27‐kDa protein. Eur. J. Biochem. 1995; 228: 381–387, [PUBMED], [INFOTRIEVE]
- Nakayama T., Hara A., Yashiro K., Sawada H. Reductases for carbonyl compounds in human liver. Biochem. Pharmacol. 1985; 34(1)107–117, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Nicklasson M., Björkman S., Roth B., Jönsson M., Höglund P. Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans. Chirality 2002; 14(8)643–652, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Nobilis M., Kopecký J., Květina J., Svoboda Z., Pour M., Kuneš J., Holčapek M., Kolářová L. Comparative biotransformation and disposition studies of nabumetone in humans and minipigs using high‐performance liquid chromatography with ultraviolet, fluorescence and mass spectrometric detection. J. Pharm. Biomed. Anal. 2003; 32(4–5)641–656, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ohara H., Miyabe Y., Deyashiki Y., Matsuura K., Hara A. Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver. Biochem. Pharmacol. 1995; 50(2)221–227, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Oppermann U. C.T., Maser. Molecular and structural aspects of xenobiotic carbonyl metabolizing enzymes. Role of reductases and dehydrogenases in xenobiotic phase I reactions. Toxicology 2000; 144: 71–81, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Oppermann U. C.T., Filling C., Jörnvall H. Forms and functions of human SDR enzymes. Chem. Biol. Interact. 2001; 130–132: 699–705, [CROSSREF]
- Oppermann U., Filling C., Hult M., Shafqat N., Wu X., Lindh M., Shafqat J., Nordling E., Kallberg Y., Persson B., Jörnvall H. Short‐chain dehydrogenases/reductases (SDR): the 2002 update. Chem. Biol. Interact. 2003; 143–144: 247–253, [CROSSREF]
- Ortiz de Montellano P. R., Mathews J. M., Langry K. C. Autocatalytic inactivation of cytochrome P450 and chloroperoxidase by 1‐aminobenzotriazole and other aryne precursors. Tetrahedron 1984; 40(3)511–519, [CROSSREF]
- Parkinson A. Biotransformation of xenobiotics. Casarett and Doull's Toxicology: The Basic Science of Poisons5th ed. McGraw‐Hill Companies, Inc., New York 1996; 113–186
- Penning T. M. Hydroxysteroid dehydrogenases: new drug targets of the aldo‐keto reductase superfamily. Adv. Exp. Med. Biol. 1997; 414(6)475–490, [PUBMED], [INFOTRIEVE], [CSA]
- Penning T. M., Jez J. M. Enzyme redesign. Chem. Rev 2001; 101(10)3027–3046, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Persson B., Heykants J., Hedner T. Clinical pharmacokinetics of ketanserin. Clin. Pharmacokinet. 1991; 20(4)263–279, [PUBMED], [INFOTRIEVE]
- Persson B., Kallberg Y., Oppermann U., Jörnvall H. Coenzyme‐based functional assignments of short‐chain dehydrogenases/reductases (SDRs). Chem. Biol. Interact. 2003; 143–144: 271–278, [CROSSREF]
- Porter S. J., Somogyi A. A., White J. M. Kinetics and inhibition of the formation of 6β‐naltrexol from naltrexone in human liver cytosol. Br. J. Clin. Pharmacol. 2000; 50: 465–471, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rady‐Pentek P., Mueller R., Tang B. K., Kalow W. Interindividual variation in the enzymatic 15‐keto‐reduction of 13,14‐dihydro‐15‐keto‐prostaglandin E1 in human liver and in human erythrocytes. Eur. J. Clin. Pharmacol. 1997; 52(2)147–153, [CROSSREF], [CSA]
- Rekka E. A., Soldan M., Belai I., Netter K. J., Maser E. Biotransformation and detoxification of insecticidal metyrapone analogues by carbonyl reduction in the human liver. Xenobiotica 1996; 26(12)1221–1229, [PUBMED], [INFOTRIEVE], [CSA]
- Rosemond M. J.C., St. John‐Williams L., Yamaguchi T., Fujishita T., Walsh J. S. Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S‐1360: role of human liver cytosolic aldo‐keto reductases. Chem. Biol. Interact. 2004; 147: 129–139, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ross D., Kepa J. K., Winski S. L., Beall H. D., Anwar A., Siegel D. NAD(P)H: quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem. Biol. Interact. 2000; 129: 77–97, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rossi M. Structural studies of metyrapone: a potent inhibitor of cytochrome P‐450. J. Med. Chem. 1983; 26(9)1246–1252, [PUBMED], [INFOTRIEVE]
- Rush W. R., Alexander O. F., Hall D. J., Dow R. J., Tokes L., Kurz L., Graham D. J.M. The metabolism of nafimidone hydrochloride in the dog, primates, and man. Xenobiotica 1990; 20(1)123–132, [PUBMED], [INFOTRIEVE]
- Sanli G., Dudley J. I., Blaber M. Structural biology of the aldo‐keto reductase family of enzymes. Cell Biochem. Biophys. 2003; 38: 79–101, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Sarges R., Schnur R. C., Belletire J. L., Peterson M. J. Spirohydantoin aldose reductase inhibitors. J. Med. Chem. 1988; 31(1)230–243, [PUBMED], [INFOTRIEVE], [CSA]
- Sato S., Yamamoto I. Enzyme immunoassays for β‐adrenoreceptor blocking agent, befunolol and its main metabolite, M1. J. Immunoassay 1983; 4(4)351–371, [PUBMED], [INFOTRIEVE]
- Sawada H., Hara A., Nakayama T., Usui S., Hayashibara M. Comparative studies on distribution and properties of carbonyl reductase in mammalian tissues. Prog. Clin. Biol. Res. 1982; 114: 275–289, (Enzymology of carbonyl metabolism: aldehyde dehydrogenase and aldo/keto reductase)[PUBMED], [INFOTRIEVE]
- Seddon B., Kelland L. R., Workman P. Bioreductive prodrugs for cancer therapy. Methods Mol. Med. 2004; 90(5)515–542, [PUBMED], [INFOTRIEVE], [CSA]
- Shah R. R. Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view. Xenobiotica 1993; 23(11)1159–1193, [PUBMED], [INFOTRIEVE], [CSA]
- Shah A., Lanman R., Bhargava V., Weir S., Hahne W. Pharmacokinetics of dolasetron following single‐ and multiple‐dose intravenous administration to normal male subjects. Biopharm. Drug Dispos. 1995; 16(3)177–189, [PUBMED], [INFOTRIEVE], [CSA]
- Shimoda K., Shibasaki M., Inaba T., Cheung S. W., Someya T., Takahashi S. Carbonyl reduction of timiperone in human liver cytosol. Pharmacol. Toxicol. 1998a; 83: 164–168, [PUBMED], [INFOTRIEVE], [CSA]
- Shimoda K., Someya T., Morita S., Hirokane G., Yokono A., Shibasaki M., Takahashi S. Plasma concentrations of timiperone and its reduced metabolite in the patients on timiperone. Psychiatry Clin. Neurosci. 1998b; 52(5)535–540, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Shiraishi H., Ishikura S., Matsuura K., Deyashiki Y., Ninomiya M., Sakai S., Hara A. Sequence of the cDNA of a human dihydrodiol dehydrogenase isoform (AKR1C2) and tissue distribution of its mRNA. Biochem. J. 1998; 334: 399–405, [PUBMED], [INFOTRIEVE]
- Skálová L., Nobilis M., Szotáková B., Kondrová E., Šavlik M., Wsól V., Pichard‐Garcia L., Maser E. Carbonyl reduction of the potential cytostatic drugs benfluron and 3,9‐dimethoxybenfluron in human in vitro. Biochem. Pharmacol. 2002; 64(2)297–305, [CROSSREF], [CSA]
- Skálová L., Král R., Szotáková B., Babú Y. N., Pichard‐Garcia L., Wsól V. Chiral aspects of metabolism of antiinflammatory drug flobufen in human hepatocytes. Chirality 2003; 15(5)433–440, [CROSSREF], [CSA]
- Someya T., Inaba T., Tyndale R. F., Tang S. W., Takahashi S. Conversion of bromperidol to reduced bromperidol in human liver. Neuropsychopharmacology 1991; 5(3)77–182
- Stewart P. M. 11β‐Hydroxysteroid dehydrogenase: implications for clinical medicine. Clin. Endocrinol. 1996; 44: 493–499, [CROSSREF]
- Stewart P. M., Krozowski Z. S. 11β‐hydroxysteroid dehydrogenase. Vitam. Horm. 1999; 57: 249–324, [PUBMED], [INFOTRIEVE], [CSA]
- Stewart P. M., Murry B. A., Mason J. I. Human kidney 11β‐hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide‐dependent enzyme and differs from the cloned type I isoform. J. Clin. Endocrinol. Metab. 1994; 79(2)480–484, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Suzen S., Buyukbingol E. Recent studies of aldose reductase enzyme inhibition for diabetic complications. Curr. Med. Chem. 2003; 10(15)1329–1352, [PUBMED], [INFOTRIEVE]
- Takanashi S., Bachur N. R. Daunorubicin metabolites in human urine. J. Pharmacol. Exp. Ther. 1975; 195(1)41–49, [PUBMED], [INFOTRIEVE]
- Takanashi S., Bachur N. R. Adriamycin metabolism in man: evidence from urinary metabolites. Drug Metab. Dispos. 1976; 4(1)79–87, [PUBMED], [INFOTRIEVE]
- Takasaki W., Tanaka Y. Application of antibody‐mediated extraction for the stereoselective determination of the active metabolite of loxoprofen in human and rat plasma. Chirality 1992; 4(5)308–315, [PUBMED], [INFOTRIEVE]
- Testa B. Chiral aspects of drug metabolism. Trends Pharmacol. Sci. 1986; 7: 60–64, [CROSSREF]
- Testa B. Dehydrogenation of alcohols and aldehydes, carbonyl reduction. The Metabolism of Drugs and Other Xenobiotics: Biochemistry of Redox Reactions. Academic Press Limited, London 1995; 41–69
- Usami N., Kitahara K., Ishikura S., Nagano M., Sakai S., Hara A. Characterization of a major form of human isatin reductase and the reduced metabolite. Eur. J. Biochem. 2001; 268: 5755–5763, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Usami N., Yamamoto T., Shintani S., Higaki Y., Ishikura S., Katagiri Y., Hara A. Substrate specificity of human 3(20)α‐hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol. Pharm. Bull. 2002; 25(4)441–445, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Vickers S., Duncan C. A., Kari P. H., Homnick C. F., Elliott J. M., Pitzenberger S. M., Hichens M., Vyas K. P. In vivo and in vitro metabolism studies on a class III antiarrhythmic agent. Drug Metab. Dispos. 1993; 21(3)467–473, [PUBMED], [INFOTRIEVE]
- Voice M. W., Seckl J. R., Edwards C. R.W., Chapman K. E. 11β‐hydroxysteroid dehydrogenase type 1 expression in 2S FAZA hepatoma cells is hormonally regulated: a model system for the study of hepatic glucocorticoid metabolism. Biochem. J. 1996; 317: 621–625, [PUBMED], [INFOTRIEVE], [CSA]
- Volosov A., Xiaodong S., Perucca E., Yagen B., Sintov A., Bialer M. Enantioselective pharmacokinetics of 10‐hydroxycarbazepine after oral administration of oxcarbazepine to healthy chinese subjects. Clin. Pharmacol. Ther. 1999; 66(6)547–553, [PUBMED], [INFOTRIEVE], [CSA]
- Vree T. B., Maljers L., Van den Borg N., Nibbering N. M.M., Verwey‐van Wissen C. P., Lagerwerf A. J., Maes R. A., Jongen P. J. High‐performance liquid‐chromatographic‐atmospheric‐pressure chemical‐ionization ion‐trap mass‐spectrometric identification of isomeric C6‐hydroxy and C20‐hydroxy metabolites of methylprednisolone in the urine of patients receiving high‐dose pulse therapy. J. Pharm. Pharmacol. 1999; 51(10)1155–1166, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Walker B. R., Seckl J. R. 11β‐hydroxysteroid dehydrogenase type 1 as a novel therapeutic target in metabolic and neurodegenerative disease. Expert Opin. Ther. Targets 2003; 7(6)771–783, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Walsh J. S., Reese M. J., Thurmond L. M. The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes. Chem. Biol. Interact. 2002; 142: 135–154, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Weil A., Caldwell J., Guichard J. P., Picot G. Species differences in the chirality of the carbonyl reduction of [14C] fenofibrate in laboratory animals and humans. Chirality 1989; 1(3)197–201, [PUBMED], [INFOTRIEVE]
- Welles J. S., Root M. A., Anderson R. C. Metabolic Reduction of 1‐(p‐acetylbenzenesulfonyl)‐3‐cyclohexylurea (acetohexamide) in different species. Proc. Soc. Exp. Biol. Med. 1961; 107: 583–585, [PUBMED], [INFOTRIEVE]
- Wermuth B., Münch J. D.B., von Wartburg J. P. Purification and properties of NADPH dependent aldehyde reductase from human liver. J. Biol. Chem. 1977; 252(11)3821–3828, [PUBMED], [INFOTRIEVE]
- Winters C. J., Molowa D. T., Guzelian P. S. Isolation and characterization of cloned cDNAs encoding human liver chlordecone reductase. Biochemistry 1990; 29(4)1080–1087, [PUBMED], [INFOTRIEVE]
- Wirth H., Wermuth B. Immunohistochemical localization of carbonyl reductase in human tissues. J. Histochem. Cytochem. 1992; 40(12)1857–1863, [PUBMED], [INFOTRIEVE]
- Wsól V., Szotáková B., Kvasničková E., Fell A. F. High‐performance liquid chromatography study of stereospecific microsomal enzymes catalysing the reduction of a potential cytostatic drug, oracin. Interspecies comparison. J. Chromatogr. A 1998; 797(1–2)197–201
- Wsól V., Szotáková B., Trejtnar F., Skálová L., Kvasničková E. Chiral aspects of drug interactions with biological systems. Chem. Papers 1998; 52: 556
- Wsól V., Szotáková B., Skálová L., Cepkova H., Kvasničková E. The main metabolic pathway of oracin, a new potential cytostatic drug, in human liver microsomes and cytosol: stereoselectivity of reoxidation of the principal metabolite 11‐dihydrooracin to oracin. Enantiomer 2000; 5(3–4)263–270, [CSA]
- Wu K., Knox R., Sun X. Z., Joseph P., Jaiswal A. K., Zhang D., Deng P. S.K., Chen S. Catalytic properties of NAD(P)H: quinone oxidoreductase‐2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. Arch. Biochem. Biophys. 1997; 347(2)221–228, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]